Vasoactive intestinal polypeptide induces analgesia and impairs the antinociceptive effect of morphine in mice

Vasoactive intestinal polypeptide (VIP) has numerous regulatory roles in peripheral, endocrine organs and in the central nervous system. The present study related to the effects of centrally (intracerebroventricularly) administered VIP on pain sensitivity and on opiate tolerance and dependence in intact male CFLP mice. VIP was analgesic when administered alone centrally. Naloxone treatment abolished this analgesic effect. VIP decreased the analgesic effect of a single subcutaneous morphine injection and the development of chronic tolerance to morphine. Morphine withdrawal signs were not significantly affected after VIP pretreatment. These findings indicate that VIP may play a role in pain sensitivity and that an opiate component may participate in this effect.